Network origin in Tamara Louw first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 22 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Tamara Louw via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer Founder Director of Finance/CFO Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer | ||
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Chief Executive Officer | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Investor Relations Contact General Counsel | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Director/Board Member | |
Tessellate Bio BV
 Tessellate Bio BV BiotechnologyHealth Technology Tessellate Bio BV is a Dutch preclinical stage biotechnology company that focuses on discovering and developing precision oncology medicines. The company is based in Naarden, the Netherlands. The company's mission is to turn cancer patients into cancer survivors by targeting unexplored or difficult to drug pathways beyond HRD. The company is also developing companion diagnostics, including a potentially diagnostic to detect ALT positive cancers. Led by an experienced team of drug hunters, Tessellate Bio is building a pipeline of first-in-class medicines based on cutting-edge research. The company was founded by Hilda A. Pickett and the CEO is Andree Blaukat. | Biotechnology | Director/Board Member | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| NOVIMMUNE SA | Medical/Nursing Services | Director of Finance/CFO | |
| Wuerzburg Schweinfurt University of Applied Sciences | College/University | Masters Business Admin | |
| Atlantic Pharmaceuticals (Holdings) Ltd. | Director/Board Member | ||
| Boston University | College/University | Masters Business Admin | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director of Finance/CFO | |
| MedCity Ltd. | Chairman | ||
| Spinifex Pty Ltd. | Director/Board Member | ||
| ARYA SCIENCES ACQUISITION CORP V | Financial Conglomerates | Founder | |
| EleGene AG | Director of Finance/CFO | ||
| Creabilis SA | Chief Executive Officer | ||
F-Star Beta Ltd.
 F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
| AVERY DENNISON CORPORATION | Containers/Packaging | Director of Finance/CFO | |
F-star Alpha Ltd.
 F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
| F-STAR THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Levicept Ltd.
 Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chief Executive Officer | |
Xontogeny LLC
 Xontogeny LLC Pharmaceuticals: MajorHealth Technology Xontogeny LLC operates biotech aggregator company. The firm offers entrepreneurs with guidance and operational support in drug and technology development. The company was founded by Christopher Nishan Garabedian and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
Perceptive Advisors LLC
 Perceptive Advisors LLC Investment ManagersFinance Perceptive Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Joseph “Joe” Edelman in 1999. provides investment advice to private funds, separate accounts, and co-investment vehicles. Investors in the client accounts and co-investment vehicles consist primarily of institutional investors, financial institutions, other investment funds, and high-net-worth individuals. | Investment Managers | Chief Investment Officer | |
| PROTALIX BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
| Princeton University | College/University | Undergraduate Degree | |
| SOLID BIOSCIENCES INC. | Biotechnology | Director/Board Member | |
Perceptive Advisors (Private Equity)
 Perceptive Advisors (Private Equity) Investment ManagersFinance Perceptive Advisors (Private Equity) (Perceptive Advisors) is a private equity subsidiary of Perceptive Advisors LLC founded in 1999 by Joseph Eric Edelman. The firm is headquartered in New York. | Investment Managers | Chief Investment Officer | |
Ochre Bio Ltd.
 Ochre Bio Ltd. Pharmaceuticals: MajorHealth Technology Ochre Bio Ltd. is a biotechnology company based in Headington, UK. Ochre Bio is focused on developing RNA medicines for chronic liver diseases. The British company uses deep phenotyping, precision RNA medicine, and testing in live human donor livers to develop therapies for important liver health challenges. The company's goal is to develop therapies that increase donor liver supply and reduce cirrhosis complications. The company was founded by Quin Wills and the CEO is Jack O'Meara. | Pharmaceuticals: Major | Chairman | |
Immunocore Ltd.
 Immunocore Ltd. Pharmaceuticals: MajorHealth Technology Part of Immunocore Holdings Plc, Immunocore Ltd. is a British commercial-stage biotechnology company that develops and commercializes transformative medicines to address unmet needs in cancer, infection, and autoimmune disease. The company is based in Oxon, UK. The company has a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications, built on their proprietary soluble TCR bi-specific Immtac® platform. The company was founded in 2007, and the CEO is Bahija Jallal. | Pharmaceuticals: Major | Chief Executive Officer | |
| LIANBIO | Biotechnology | Chief Executive Officer | |
Genomics England Ltd.
 Genomics England Ltd. Miscellaneous Commercial ServicesCommercial Services Genomics England Ltd. runs and delivers 100,000 genomes project. Its flagship project sequences 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. The company was founded by Jeremy Hunt on July 5, 2013 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
| Germany | 16 |
| United States | 14 |
| United Kingdom | 12 |
| Switzerland | 3 |
| France | 2 |
Sectoral
| Health Technology | 30 |
| Finance | 6 |
| Consumer Services | 5 |
| Commercial Services | 3 |
| Technology Services | 2 |
Operational
| Director/Board Member | 109 |
| Corporate Officer/Principal | 44 |
| Chief Executive Officer | 37 |
| Chairman | 32 |
| Independent Dir/Board Member | 25 |
Most connected contacts
| Insiders | |
|---|---|
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Peter Chambré | 23 |
| Mathias Hothum | 19 |
| Adam Stone | 18 |
| Michael Atieh | 16 |
| Carsten Reinhardt | 16 |
| Arnd Christ | 15 |
| Heather Mason | 13 |
| Paul Carter | 12 |
| Rainer Kramer | 10 |
| Nancy Valente | 8 |
| Jordan Silverstein | 7 |
| Edward Sturchio | 5 |
| Cedrik M. Britten | 5 |
- Stock Market
- Insiders
- Tamara Louw
- Company connections
